Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
Resverlogix Corp.
RVXResverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company's lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions. It has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company is headquartered in Calgary, Canada. Address: 4820 Richard Road SW, Calgary, AB, Canada, T3E 6L1
Analytics
Objectif de Cours de WallStreet
11.06 CADRatio C/B
–Rendement du dividende
–Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés RVX
Analyse des dividendes RVX
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–Croissance des dividendes sur 5 ans
–Croissance continue
–Ratio de distribution Moyenne sur 5 ans
–Historique des dividendes RVX
Valorisation des titres RVX
financières RVX
Résultats | 2019 | Dynamique |